Pemetrexed for the treatment of advanced ovarian cancer
Objective To evaluate the efficacy and side effects for chemotherapy with pemetrexed combined with cisplatin in the treatment of advanced ovarian cancer. Methods The study was conducted on 41 patients with advanced ovarian cancer who had failed to previous chemotherapy and all these patients had been confirmed with pathology or cytology. Among the 41 cases, the median age was 48 years old, KPS scale was 60-100,received pemetrexed 500mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenous infusion, with 21 days as one cycle. All patients who received 2 or more cycles could be evaluated. Results There was no case with complete response, 17 cases got partial response, 15 got stable disease and 6 cases got progression disease. So the overall response rate was 44.74%. The clinical benefit rate was 84.21%. The median time to diease progression was 5.3 months and the median survival time was 13.2 months. The 1-year survival rate was 34.21%. The common adverse effects were leucopenia, anemia and gastrointestinal response. Conclusions Chemotherapy with pemetrexed combined with cisplatin is effective and feasible for advanced ovarian cancer. So pemetrexed is one of the choices for advanced ovarian cancer patients who need two or more line therapy.
NETL
NSTL
万方数据
维普
